Climb Bio's Budoprutug Signals a New Era for Autoimmune Therapy

WELLESLEY HILLS, Mass. – May 05, 2026 – Clinical-stage biotechnology company Climb Bio (Nasdaq: CLYM) today captured the attention of the medical and financial communities with a series of significant updates on its lead therapeutic candidate, budoprutug. During a virtual R&D Spotlight event, the company unveiled positive topline data for a new subcutaneous formulation of the drug, highlighted its potential to treat a broad spectrum of B-cell mediated diseases, and set a clear timeline for critical data readouts expected later this year.

The announcements suggest that Climb Bio is positioning budoprutug not just as an incremental improvement, but as a potential paradigm shift in how complex autoimmune diseases like primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE) are treated.

“Budoprutug represents a differentiated and potentially expansive opportunity within the immune-mediated disease landscape,” said Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer of Climb Bio, in a statement. “We believe there is substantial potential for budoprutug across a range of immune-mediated diseases, and we look forward to the additional milestones anticipated this year.”

A Patient-Centric Advance in Drug Delivery

The most immediate news from the event was the success of a Phase 1 trial for a subcutaneous (SC) formulation of budoprutug in healthy volunteers. The data showed that the SC injection achieved robust B-cell depletion comparable to that of the traditional intravenous (IV) formulation at matched doses. Furthermore, the SC version was found to be generally safe and well-tolerated.

This development is more than a technical achievement; it represents a significant step toward improving patient quality of life and broadening clinical adoption. Many existing biologic therapies for autoimmune diseases require lengthy and inconvenient IV infusions in a hospital or clinic setting. An effective SC formulation allows for simple self-administration at home, a feature that could dramatically improve patient adherence and make the therapy accessible to a much wider population.

Climb Bio confirmed that the encouraging results support advancing the SC formulation into studies with autoimmune disease patients to optimize the dosing regimen. The parallel development of both IV and SC versions provides strategic flexibility, allowing the therapy to be tailored to different patient needs and healthcare settings.

The Scientific Edge: Moving Beyond CD20

At the core of budoprutug’s potential is its mechanism of action: targeting a protein called CD19. For years, the standard for B-cell depletion therapy has been drugs that target CD20, like rituximab. While effective, these therapies have limitations because CD20 is not present on the full spectrum of B-cells that cause autoimmune disease.

As highlighted during the company’s presentation, which featured insights from Professor David Jayne of the University of Cambridge, CD19 is emerging as a preferred target. CD19 is expressed more broadly across the B-cell lineage, including on early B-cells and, crucially, on plasmablasts—the cells that mature into autoantibody factories. By targeting CD19, budoprutug has the potential to achieve a more profound and comprehensive depletion of the cells responsible for producing the pathogenic autoantibodies that drive diseases like lupus and pMN.

Budoprutug is engineered with an enhanced design and high affinity for its target, aiming to drive rapid and durable depletion of these harmful cells. Early clinical data in pMN has already hinted at this potential, showing long-term disease control and reductions in autoantibodies. This scientific differentiation is a key pillar of Climb Bio's strategy to address the significant unmet needs in patient populations that do not respond adequately to existing treatments.

A Pipeline Packed with Catalysts

Climb Bio is advancing budoprutug across three high-need indications, with clinical trials enrolling to plan and a cascade of data readouts poised to serve as major catalysts in 2026.

• Immune Thrombocytopenia (ITP): This autoimmune bleeding disorder, affecting an estimated 85,000 people in the U.S., will be the first to yield new data. Initial results on B-cell and platelet counts from the low-dose cohort of a Phase 1b/2a study are expected in June 2026.

• Primary Membranous Nephropathy (pMN): A rare and serious kidney disease affecting about 75,000 U.S. adults, pMN is a key focus for budoprutug. The drug has already received both Fast Track and Orphan Drug designations from the FDA for this indication, potentially streamlining its path to approval. Initial data from a Phase 2 study, including B-cell and anti-PLA2R autoantibody levels, are anticipated in the fourth quarter of 2026.

• Systemic Lupus Erythematosus (SLE): Affecting an estimated 240,000 people in the U.S., SLE is a notoriously complex autoimmune disease. Climb Bio is running a global Phase 1b study and expects to report initial B-cell data in the fourth quarter of 2026.

This multi-pronged strategy allows the company to maximize its learning about the drug's effects across different diseases while pursuing substantial market opportunities.

Wall Street Takes Notice

The promise of Climb Bio’s pipeline has not gone unnoticed by the financial markets. The company's stock (CLYM) has seen a remarkable surge over the past year, gaining over 675% and trading near its 52-week high. This investor enthusiasm is backed by strong analyst sentiment, with a consensus "Buy" rating and price targets suggesting significant further upside.

Analysts from firms like Mizuho and BTIG have pointed to budoprutug’s differentiated mechanism and the vast commercial potential in its target indications as key drivers of value. The company’s financial position was recently fortified by a $110 million private financing from a syndicate of leading healthcare investors.

With cash reserves now expected to fund operations into 2028, Climb Bio is well-capitalized to see its programs through their upcoming critical milestones. This strong financial footing removes near-term funding concerns and allows management to focus squarely on execution.

With a differentiated scientific approach, a patient-friendly formulation in development, and a series of high-impact clinical milestones on the immediate horizon, Climb Bio is at a pivotal moment. The data readouts expected in the coming months will provide the first clear verdict on whether budoprutug can deliver on its immense promise and redefine the standard of care for millions living with autoimmune disease.